Literature DB >> 12324653

Activins, inhibins, and follistatins: from endocrinology to signaling. A paradigm for the new millennium.

Corrine Welt1, Yisrael Sidis, Henry Keutmann, Alan Schneyer.   

Abstract

It has been 70 years since the name inhibin was used to describe a gonadal factor that negatively regulated pituitary hormone secretion. The majority of this period was required to achieve purification and definitive characterization of inhibin, an event closely followed by identification and characterization of activin and follistatin (FS). In contrast, the last 15-20 years saw a virtual explosion of information regarding the biochemistry, physiology, and biosynthesis of these proteins, as well as identification of activin receptors, and a unique mechanism for FS action-the nearly irreversible binding and neutralization of activin. Many of these discoveries have been previously summarized; therefore, this review will cover the period from the mid 1990s to present, with particular emphasis on emerging themes and recent advances. As the field has matured, recent efforts have focused more on human studies, so the endocrinology of inhibin, activin, and FS in the human is summarized first. Another area receiving significant recent attention is local actions of activin and its regulation by both FS and inhibin. Because activin and FS are produced in many tissues, we chose to focus on a few particular examples with the most extensive experimental support, the pituitary and the developing follicle, although nonreproductive actions of activin and FS are also discussed. At the cellular level, it now seems that activin acts largely as an autocrine and/or paracrine growth factor, similar to other members of the transforming growh factor beta superfamily. As we discuss in the next section, its actions are regulated extracellularly by both inhibin and FS. In the final section, intracellular mediators and modulators of activin signaling are reviewed in detail. Many of these are shared with other transforming growh factor beta superfamily members as well as unrelated molecules, and in a number of cases, their physiological relevance to activin signal propagation remains to be elucidated. Nevertheless, taken together, recent findings suggest that it may be more appropriate to consider a new paradigm for inhibin, activin, and FS in which activin signaling is regulated extracellularly by both inhibin and FS whereas a number of intracellular proteins act to modulate cellular responses to these activin signals. It is therefore the balance between activin and all of its modulators, rather than the actions of any one component, that determines the final biological outcome. As technology and model systems become more sophisticated in the next few years, it should become possible to test this concept directly to more clearly define the role of activin, inhibin, and FS in reproductive physiology.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12324653     DOI: 10.1177/153537020222700905

Source DB:  PubMed          Journal:  Exp Biol Med (Maywood)        ISSN: 1535-3699


  78 in total

1.  Immunohistochemical labeling of the inhibin/activin betaC subunit in normal human placental tissue and chorionic carcinoma cell lines.

Authors:  Tobias Weissenbacher; Ansgar Brüning; Tanja Kimmich; Josef Makovitzky; Andrea Gingelmaier; Ioannis Mylonas
Journal:  J Histochem Cytochem       Date:  2010-05-10       Impact factor: 2.479

Review 2.  Development and function of the human fetal adrenal cortex: a key component in the feto-placental unit.

Authors:  Hitoshi Ishimoto; Robert B Jaffe
Journal:  Endocr Rev       Date:  2010-11-04       Impact factor: 19.871

3.  Overexpression of follistatin in the mouse epididymis disrupts fluid resorption and sperm transit in testicular excurrent ducts.

Authors:  Darcie D Seachrist; Emhonta Johnson; Christianne Magee; Colin M Clay; James K Graham; D N Rao Veeramachaneni; Ruth A Keri
Journal:  Biol Reprod       Date:  2012-08-23       Impact factor: 4.285

4.  FSTL3 deletion reveals roles for TGF-beta family ligands in glucose and fat homeostasis in adults.

Authors:  Abir Mukherjee; Yisrael Sidis; Amy Mahan; Michael J Raher; Yin Xia; Evan D Rosen; Kenneth D Bloch; Melissa K Thomas; Alan L Schneyer
Journal:  Proc Natl Acad Sci U S A       Date:  2007-01-17       Impact factor: 11.205

5.  TCDD increases inhibin A production by human luteinized granulosa cells in vitro.

Authors:  H M Ho; Ken-Ichi Ohshima; Gen Watanabe; Kazuyoshi Taya; E Y Strawn; Reinhold J Hutz
Journal:  J Reprod Dev       Date:  2006-04-21       Impact factor: 2.214

6.  Molecular cloning and characterization of follistatin in the gilthead sea bream, Sparus aurata.

Authors:  Bruria Funkenstein; Yanai Rebhan; Tal Skopal
Journal:  Mol Biol Rep       Date:  2008-01-01       Impact factor: 2.316

7.  Hysterectomy Uniquely Impacts Spatial Memory in a Rat Model: A Role for the Nonpregnant Uterus in Cognitive Processes.

Authors:  Stephanie V Koebele; Justin M Palmer; Bryanna Hadder; Ryan Melikian; Carly Fox; Isabel M Strouse; Dale F DeNardo; Christina George; Emily Daunis; Adrianna Nimer; Loretta P Mayer; Cheryl A Dyer; Heather A Bimonte-Nelson
Journal:  Endocrinology       Date:  2019-01-01       Impact factor: 4.736

8.  Inhibin/activin subunits alpha, beta-A and beta-B are differentially expressed in normal human endometrium throughout the menstrual cycle.

Authors:  Ioannis Mylonas; Udo Jeschke; Irmgard Wiest; Anna Hoeing; Julia Vogl; Naim Shabani; Christina Kuhn; Sandra Schulze; Markus S Kupka; Klaus Friese
Journal:  Histochem Cell Biol       Date:  2004-10-12       Impact factor: 4.304

Review 9.  Follistatin as potential therapeutic target in prostate cancer.

Authors:  Maria Vittoria Sepporta; Francesca Maria Tumminello; Carla Flandina; Marilena Crescimanno; Marco Giammanco; Maurizio La Guardia; Danila di Majo; Gaetano Leto
Journal:  Target Oncol       Date:  2013-03-01       Impact factor: 4.493

10.  Differential expression of follistatin and FLRG in human breast proliferative disorders.

Authors:  Enrrico Bloise; Henrique L Couto; Lauretta Massai; Pasquapina Ciarmela; Marzia Mencarelli; Lavinia E Borges; Michela Muscettola; Giovanni Grasso; Vania F Amaral; Geovanni D Cassali; Felice Petraglia; Fernando M Reis
Journal:  BMC Cancer       Date:  2009-09-09       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.